High-dose alkylating agent chemotherapy with autologous bone marrow support in patients with stage III/IV epithelial ovarian cancer

High dose chemotherapy in ovarian cancer

“…Despite the low number of patients included in these exploratory studies, the HDC yield consistent results with strikingly high global (50-85%) and complete (10-40%) clinical response rates (8)(9)(10)(11)(12)(13)(14) . The high response rates observed in patients with relapsed/ persistent ovarian cancer suggests the possibility that there is a threshold beyond which high doses, such as those attained with stem cell support, yield further improvement of benefit.…”

High dose chemotherapy in ovarian cancer

“…Despite the low number of patients included in these exploratory studies, the HDC yield consistent results with strikingly high global (50–85%) and complete (10–40%) clinical response rates (8–14) . The high response rates observed in patients with relapsed/persistent ovarian cancer suggests the possibility that there is a threshold beyond which high doses, such as those attained with stem cell support, yield further improvement of benefit.…”

Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study

“…HDC was originally developed in ovarian cancer as consolidation or salvage therapy in patients with prior conventional chemotherapy. 7,8,[23][24][25][26][27][28][29][30] Moreover, only a limited number of patients received this strategy as firstline treatment, essentially as consolidation after induction treatment. 8,13,23,28,31 Addressing this issue, the French GINECO group performed a randomised study evaluating the impact of a single course of HDC with autologous stem cell support as consolidation in AOC with low tumour burden following initial conventional chemotherapy, compared to 3 additional conventional chemotherapy cycles.…”